Entresto
A pill used to treat certain types of chronic heart failure, when the heart cannot pump or fill with blood properly.
Cosentyx
An injection for inflammatory conditions including psoriasis, some forms of arthritis and a chronic skin disease called hidradenitis suppurativa.
Kisqali
A cancer medicine used with hormone treatment for certain types of breast cancer.
Kesimpta
A monthly self-injection for adults with relapsing forms of multiple sclerosis, a disease in which the immune system damages nerves.
Pluvicto
An intravenous treatment that delivers radioactive particles to certain prostate cancer cells.
Leqvio
An injection given by a health professional to lower low-density lipoprotein (LDL) cholesterol, a type of fat in the blood.
Novartis researches, tests, manufactures and sells prescription medicines in about 120 countries (2025, high). Its research focuses on heart, kidney and metabolic diseases, immune disorders, brain and nerve diseases, and cancer. Net sales were USD 54.532 billion (FY2025, high).
基于 Novartis AG 自己向美国证券交易委员会(SEC)提交的申报文件。数字如实呈报,每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议,也不是买卖任何证券的推荐。
The themes Novartis is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$160.53+0.2%11月13日 收盘
数据截至2026年9月30日,来自2026年10月27日提交的6-K
Novartis sells prescription medicines for heart disease, cancer and immune disorders to drug wholesalers, pharmacies, hospitals and health systems.
Grade A
价格下方的色带显示每个日期的评级,仅依据当时已公开的文件计算。
显示 Novartis AG 评级历史 29 个季度中的 2 个。 其余 27 个可回溯到 2018年1月。